FDA Grants Orphan Drug Status To Eisai's Investigational Compound (E7777) For Cutaneous T-Cell Lymphoma

WOODCLIFF LAKE, N.J., Aug. 8, 2013 -- (Healthcare Sales &Marketing Network) -- Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its investigational compound (E7777) for cutaneous t-cell ly... Biopharmaceuticals, Oncology, FDAEisai, orphan drug, E7777, cutaneous t-cell lymphoma
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news

Related Links:

We report a patient who presented with simultaneous T-lymphoblastic lymphoma, focal myeloid proliferation, and cutaneous cytotoxic T-cell lymphoma refractory to chemotherapy. The presence of myeloid and lymphoid lineages prompted genetic and molecular studies. A PDGFRA rearrangement was identified in all compartments: cutaneous, lymph node, and bone marrow. Treatment with imatinib resulted in an excellent response in cutaneous and systemic disease. We report the first case of a mature cutaneous T-cell lymphoma with PDGFRA rearrangement, expanding the spectrum of neoplasms associated with this genetic abnormality. Our case ...
Source: The American Journal of Dermatopathology - Category: Pathology Tags: Extraordinary Case Report Source Type: research
Authors: Kim SR, Lewis JM, Cyrenne BM, Monico PF, Mirza FN, Carlson KR, Foss FM, Girardi M Abstract While several systemic therapies are approved for cutaneous T cell lymphoma (CTCL), a non-Hodgkin lymphoma of skin-homing T cells that may involve lymph nodes and peripheral blood in advanced stages, relapses are common. Mutational analysis of CTCL cells has revealed frequent amplification of the MYC oncogene, and bromodomain and extraterminal (BET) protein inhibitors have been shown to repress MYC expression in various malignancies. Towards a potential novel therapy, we thus sought to examine the effect of BET inhib...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
The SATB1 protein has been the focus of two recent studies of cutaneous T-cell lymphomas. Fredholm et  al. observed a stage-related decrease of SATB1 expression in epidermotropic cutaneous T-cell lymphomas. SATB1 was negatively regulated by STAT5 through microRNA-155, which in turn triggered enhanced expression of T helper type 2 cytokines such as IL-5 and IL-9. In parallel, Sun et al. found that SATB1 expression was up-regulated by promoter demethylation in a subset of cutaneous anaplastic lymphoma and was associated with T helper type 17 polarization in patients with better therapeutic responses.
Source: Journal of Investigative Dermatology - Category: Dermatology Authors: Tags: Commentary Source Type: research
Conclusions: The presence of C. pneumoniae DNA in the blood cells is a frequent event in late stages of MF/SS and may be explained by Th2 shift and suppression of the immune system during the course of the disease. PMID: 30008645 [PubMed]
Source: Advances in Dermatology and Allergology - Category: Dermatology Tags: Postepy Dermatol Alergol Source Type: research
I read with interest the proposal of the European Organisation for Research and Treatment of Cancer (EORTC) cutaneous lymphoma task force concerning B ratings based on absolute counts of CD4+CD26 − or CD4+CD7− lymphocytes, that is, B0,
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Letter to the Editor Source Type: research
The comments on blood class in erythrodermic cutaneous T-cell lymphoma (CTCL) from E. Vonderheid are received with interest by our European Organisation for Research and Treatment of Cancer (EORTC) group. First, it should be noted that our recent EORTC consensus statement defined blood class according to flow cytometry [1] and included all patients with mycosis fungoides (MF) and Sezary syndrome (SS). E. Vonderheid commented on blood class in erythrodermic MF/SS, and it must be recognised that blood involvement is much more frequent in erythrodermic CTCL than patch, plaque and tumour stage MF p  
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Letter to the Editor Source Type: research
In this report we present a patient with subcutaneous panniculitis-like T-cell lymphoma, who has been successfully treated with mycophenolate mofetil.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Case Report Source Type: research
Authors: van der Weyden C, Bagot M, Neeson P, Darcy PK, Prince HM Abstract INTRODUCTION: Therapeutic options for mycosis fungoides and Sezary syndrome include a variety of immunomodulatory, epigenetic, and cytotoxic options, however, none has been demonstrated to be efficacious for all patients, or to deliver deep and durable responses to the majority of patients. In this review, we examine the monoclonal antibody, IPH4102, a novel agent for the treatment of cutaneous T-cell lymphoma. Areas covered: In this review, we examine data demonstrating the tissue specificity of KIR3DL2 receptor, which is highly expressed o...
Source: Expert Opinion on Investigational Drugs - Category: Drugs & Pharmacology Tags: Expert Opin Investig Drugs Source Type: research
In this study, Quisinostat (JNJ-26481585) a novel second-generation HDACi with highest potency for HDAC1, was tested on HuT78 cell line. Quantitative mass spectrometry (MS)-based proteomics after acetylated-lysine peptide enrichment and a targeted antibody-based immunoassay (DigiWest) were used as complementary technologies to assess the modifications of the acetylated proteome. As expected, several acetylated lysines of histones were increased by the HDACi. Additional acetylated non-histone proteins were modulated after treatment with Quisinostat including the nucleolin (a major nucleolar protein), the replication protein...
Source: Journal of Proteomics - Category: Biochemistry Authors: Tags: J Proteomics Source Type: research
Publication date: Available online 22 June 2018Source: American Journal of Kidney DiseasesAuthor(s): Katie Wickenden, Matthew P.M. Graham-Brown, David Veitch, John Dormer, Mark Bamford, Robin A.C. Graham-Brown, Graham Warwick, Simon Wagner, James O. BurtonSézary syndrome is a rare aggressive leukemic variant of primary cutaneous T-cell lymphoma, typically presenting with erythroderma, lymphadenopathy, and an atypical clonal T-cell population. Though it often involves the spleen and liver, we report a case of Sézary syndrome with renal involvement that was treated successfully. Visceral involvement confer...
Source: American Journal of Kidney Diseases - Category: Urology & Nephrology Source Type: research
More News: Cancer & Oncology | Cutaneous T cell lymphoma | Food and Drug Administration (FDA) | Grants | Lymphoma | Marketing | Pharmaceuticals | T-cell Lymphoma